'Ifn' presentation slideshows

Ifn - PowerPoint PPT Presentation


Introduction What’s already known?

Introduction What’s already known?

Analysis of anti-TNF-induced skin lesions reveals strong Th1 activation with some distinct immunological characteristics.

By corin
(331 views)

JORNADAS 2011 DE ACTUALIZACIÓN EN ATENCIÓN FARMACÉUTICA AL PACIENTE CON PATOLOGÍAS VÍRICAS. SOCIEDAD ESPAÑOLA DE FARMAC

JORNADAS 2011 DE ACTUALIZACIÓN EN ATENCIÓN FARMACÉUTICA AL PACIENTE CON PATOLOGÍAS VÍRICAS. SOCIEDAD ESPAÑOLA DE FARMAC

Actualización en nuevas terapias para la hepatitis C. Javier García-Samaniego Unidad de Hepatología Hospital Carlos III. CIBERehd Madrid. JORNADAS 2011 DE ACTUALIZACIÓN EN ATENCIÓN FARMACÉUTICA AL PACIENTE CON PATOLOGÍAS VÍRICAS. SOCIEDAD ESPAÑOLA DE FARMACIA HOSPITALARIA

By xia
(156 views)

FSC

FSC

pDC. medium. Flu. CL097. 20 %. 85 %. 95 %. CD40. BDCA2. CD123. FSC. GEN2.2 cells. medium. Flu. CL097. 25 %. 82 %. 97 %. CD40. SSC. FSC. FSC. 100. GEN2.2. 2.5. GENshTLR7. GEN2.2. 80. GENshTLR7. 2.0. 60. % CD40 positive cells. 1.5. relative Ct. 40. 1.0. 20. 0.5.

By masato
(136 views)

SEM and TEM images of BCNTs grown by SSP‑LPP.

SEM and TEM images of BCNTs grown by SSP‑LPP.

Design and manufacturing of large area, thick cBN films Peter X. Feng (University of Puerto Rico), DMR 0706147.

By derora
(207 views)

Adjuvant Therapy for Melanoma What is the role of PegIFN in relation to HDIFN?

Adjuvant Therapy for Melanoma What is the role of PegIFN in relation to HDIFN?

Adjuvant Therapy for Melanoma What is the role of PegIFN in relation to HDIFN?. John M. Kirkwood, MD Professor of Medicine, Dermatology and Translational Science University of Pittsburgh School of Medicine &Cancer Institute Melanoma Committee, Eastern Cooperative Oncology Group

By stew
(144 views)

Chapter 8 The interferon family

Chapter 8 The interferon family

Pharmaceutical Biotechnology. Chapter 8 The interferon family. Dr. Tarek El-Bashiti Assoc. Prof. of Biotechnology. Cytokines. Cytokines are a diverse group of regulatory proteins or glycoproteins whose classification remains somewhat diffuse (Table 8.1).

By jewel
(172 views)

CYTOKINES- ITS PROPERTIES AND FUNCTION

CYTOKINES- ITS PROPERTIES AND FUNCTION

CYTOKINES- ITS PROPERTIES AND FUNCTION. BY- CHANDANA KALITA MSC BIOTECHNOLOGY 2 nd SEM ROLL NO. 03 GAUHATI UNIVERSITY. CYTOKINES.

By varick
(196 views)

IL-10 IL-12 TNF a TNF b

IL-10 IL-12 TNF a TNF b

Macrophage. Neutrophil. B-Cell. Eosinophil. Basophil. T-Cell. Mast Cell. IFN a IFN b IFN g. IL-1 IL-6 IL-10 IL-12 IL-15 TNF a. IL-1 IL-8 TNF a. IL-10 IL-12 TNF a TNF b. IL-1 IFN a IFN b TNF a TNF b. IL-1 IFN a IL-6 IFN g IL-8 IFN a IL-10 IL-12 IL-15 IL-18. TNF a. IL-1 IL-8.

By sasson
(111 views)

Sup. Fig. 2

Sup. Fig. 2

IFN- g (pg/ml). C-REP. T-REP. MART-1 peptide ( m M). C-REP. T-REP. 18 6 2 0.67 0.22. E:T ratio. A. B. IFN- g (pg/ml). 0.5. 0. 0.1. 1. TGF- b ( ng/ml ). C. Sup. Fig. 2. 1.8. 4.2. Mart-1. CD8. CD107a. 44.2. 37.8. Mart-1. CD8.

By delano
(73 views)

Chapter 8 The interferon family

Chapter 8 The interferon family

Pharmaceutical Biotechnology. Chapter 8 The interferon family. Dr. Tarek El-Bashiti Assoc. Prof. of Biotechnology. Cytokines. Cytokines are a diverse group of regulatory proteins or glycoproteins whose classification remains somewhat diffuse (Table 8.1).

By koto
(115 views)

Harro Frauendorf

Harro Frauendorf

Harro Frauendorf. Introduction. Infection: microbes vs. host Viruses try to secure a niche for replication Host must limit pathogen's advance Type 1 interferons are key players many members: IFN- α / β Virus evolved tricks to avoid antiviral effects of IFNs (co evolution).

By morey
(161 views)

Jorge R. Oksenberg, Ph.D. Professor of Neurology University of California, San Francisco

Jorge R. Oksenberg, Ph.D. Professor of Neurology University of California, San Francisco

Mapping genetic susceptibility and modeling pathogenesis in multiple sclerosis. Fundación Ramón Areces. Madrid, 2 de Febrero de 2012. Jorge Oksenberg UCSF School of Medicine Department of Neurology jorge.oksenberg@ucsf.edu. Jorge R. Oksenberg, Ph.D. Professor of Neurology

By dacia
(115 views)

tnf- a (fold change)

tnf- a (fold change)

Figure S1. D. A. IL-12 (pg/ml). il-12 (fold change). Cytokine (pg/ml). mRNA levels. B. E. IFN g (pg/ml). ifn- g (fold change). Donor 1. Donor 1. Donor 1. Donor 1. Donor 1. Donor 1. Cytokine (pg/ml). Donor 2. Donor 2. Donor 2. Donor 2. Donor 2. Donor 2. mRNA levels. C.

By albin
(104 views)

Pius-Hospital Oldenburg

Pius-Hospital Oldenburg

Pius-Hospital Oldenburg. Frank Griesinger Professor at the University of G ö ttingen and Chair of the Department of Medical Oncology, Pius-Hospital, Oldenburg, Germany. Professor of Internal Medicine and Haematology and Medical Oncology at the University of G ö ttingen

By ira
(269 views)

B、C型肝炎治療個案照護及衛教技巧

B、C型肝炎治療個案照護及衛教技巧

B、C型肝炎治療個案照護及衛教技巧. 中山醫學大學附設醫院 肝病防治中心 張秋純 個案管理師. 個案照護及衛教的第一步 建立信任. 自 我 介 紹 ~. 善用溝通技巧. 傾聽 ~ 同理心 ~ 一次不要說太多 ~ 用對方的語言說 ~ 澄清 ~ 知識傳授 ~. 面對一個 BC 型肝炎的病人, 我要讓他知道什麼訊息 ~. 認識疾病 什麼情況需要治療 治療的重要性 治療可能需要多少時間 費用 治療方式 治療的注意事項 怎麼做可以更好 追蹤與聯絡方式. 提供資訊. 認識疾病 什麼情況需要治療 治療的重要性 治療可能需要多少時間 費用 治療方式

By darin
(1128 views)

Combination Therapy of Chronic Hepatitis Delta

Combination Therapy of Chronic Hepatitis Delta

Combination Therapy of Chronic Hepatitis Delta. Ulus Salih Akarca Ege University, Faculty of Medicine Izmir, Turkey. The logic of the combination treatment of chronic hepatitis delta. Chronicity. Lower effect of immune modulator treatments. Escape from immune system.

By awena
(188 views)

New Anti-HCV Drugs Other Drugs?

New Anti-HCV Drugs Other Drugs?

New Anti-HCV Drugs Other Drugs?. Yves Benhamou Hôpital Pitié Salpêtrière Paris. Challenges for New Anti-HCV Therapies. Improve SVR Role of direct antivirals (enzyme inhibitors) Potency – Safety – Resistance profile Improve acceptability and tolerability of current SOC

By zada
(282 views)

IL-17

IL-17

IL-17. MIF. MMP. IL-18. T1, 2. IFN - g. IL-2. Angiogenesis VEGF, FGF, HGF IL-8, angipoietin-1 Stromal cell derived GF TNF, TGF (indirect). Angiostatic IL-12, IFN -a b g, PF4. Adhesion molecules ICAM-1,2 VAM-1 *b -i ntegrin LAF-3 *P-selectin. BMP MIF. IL-17. IL-15. TNF - a

By mio
(152 views)

SKRC-1

SKRC-1

None. IFN- b. SKRC-1. R1: 0.6 R2: 44.0 R3: 44.2 R4: 10.5. R1: 0.5 R2: 50.4 R3: 33.7 R4: 14.9. R1: subG1 R2: G0/G1 R3: S R4: G2/M. Anti- BrdU -FITC. SKRC-44. R1: 3.7 R2: 33.1 R3: 43.2 R4: 13.2. R1: 2.0 R2: 44.1 R3: 29.0 R4: 18.4. R3. R2. R4. R1. 7AAD.

By feivel
(191 views)

PLSCR1

PLSCR1

Figure S2. A. SnoN mRNA Levels. 1h IFN-2 α. Untreated. 3h IFN-2 α. C. B. HEY: IFN-2 α. HEY: IFN - 2α. Control siRNA. SnoN siRNA. 6h. 6h. IFN+NAC (1000). 0h. 0h. IFN+NAC (100). IFN+NAC (500). NAC (1000). IFN only. None. 38 kDa. PLSCR1. 31 kDa. 38 kDa. PLSCR1.

By marlee
(154 views)

View Ifn PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Ifn PowerPoint presentations. You can view or download Ifn presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.